Values First Advisors Inc. Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Values First Advisors Inc. lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 51.3% in the second quarter, Holdings Channel reports. The institutional investor owned 3,947 shares of the biopharmaceutical company’s stock after selling 4,166 shares during the period. Values First Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,287,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ALNY. SVB Wealth LLC purchased a new stake in Alnylam Pharmaceuticals during the first quarter worth $27,000. Bessemer Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares during the period. Ameritas Advisory Services LLC purchased a new stake in Alnylam Pharmaceuticals during the second quarter worth $42,000. Washington Trust Advisors Inc. lifted its holdings in Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 61 shares during the period. Finally, Larson Financial Group LLC lifted its holdings in Alnylam Pharmaceuticals by 77.7% during the first quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 87 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ALNY. Needham & Company LLC upped their target price on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a report on Thursday, July 31st. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 12th. Wolfe Research raised Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a research report on Monday, August 4th. Jefferies Financial Group upped their price target on Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research report on Monday, July 7th. Finally, Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Twenty-four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $457.08.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $481.07 on Friday. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a 50-day moving average of $455.04 and a two-hundred day moving average of $350.64. The stock has a market cap of $63.06 billion, a P/E ratio of -194.77 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $488.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,924 shares of the business’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $4,034,094.20. Following the sale, the chief executive officer owned 65,409 shares in the company, valued at approximately $29,568,138.45. The trade was a 12.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the sale, the executive vice president owned 54,052 shares in the company, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.